• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

44.12 +2.00 (+4.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,188,527
Open 42.52
Bid (Size) 42.80 (500)
Ask (Size) 44.12 (300)
Prev. Close 42.12
Today's Range 42.09 - 44.70
52wk Range 13.88 - 44.70
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Travere Therapeutics to Report First Quarter 2026 Financial Results
April 27, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started? ↗
April 20, 2026
Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price gains. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+11.6%
+11.6%
1 Month
+40.4%
+40.4%
3 Month
+41.9%
+41.9%
6 Month
+25.5%
+25.5%
1 Year
+112.5%
+112.5%

More News

Read More
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 14, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
These stocks are moving in today's session ↗
April 14, 2026
Via Chartmill
Topics Artificial Intelligence
Travere Therapeutics (NASDAQ:TVTX) Posts Q4 Earnings Beat on Profitability Despite Revenue Miss ↗
February 19, 2026
Via Chartmill
Topics Earnings
News headline image
Tuesday's session: gap up and gap down stocks ↗
April 14, 2026
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
April 14, 2026
Via Chartmill
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
March 31, 2026
Via MarketMinute
News headline image
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
March 10, 2026
Via MarketMinute
News headline image
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
February 19, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
February 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
February 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
February 17, 2026
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
February 17, 2026
Via The Motley Fool
News headline image
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 11, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
February 04, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
January 25, 2026
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
January 24, 2026
Via The Motley Fool
News headline image
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
January 16, 2026
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Why Travere Therapeutics Stock Got Trounced on Tuesday ↗
January 13, 2026
Via The Motley Fool
News headline image
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS
January 13, 2026
Via MarketMinute
News headline image
Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April ↗
January 13, 2026
Via Stocktwits
News headline image
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
January 13, 2026
From Travere Therapeutics, Inc.
Via Business Wire
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
January 13, 2026
Via Chartmill

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?
Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
What is the current price of Travere Therapeutics, Inc. - Common Stock?
The current price of Travere Therapeutics, Inc. - Common Stock is 44.12
When was Travere Therapeutics, Inc. - Common Stock last traded?
The last trade of Travere Therapeutics, Inc. - Common Stock was at 05/01/26 04:00 PM ET
What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
The market capitalization of Travere Therapeutics, Inc. - Common Stock is 2.68B
How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
Travere Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap